zuranolone

An oral, positive allosteric modulator of GABA type A receptors indicated for postpartum depression.

Also Known As:

1-(3.alpha.-hydroxy-3.beta.-methyl-20-oxo-19-nor-5.beta.-pregnan-21-YL)-1H-pyrazole-4-carbonitrile; 1H-pyrazole-4-carbonitrile, 1-((3.alpha.,5.beta.)-3-hydroxy-3-methyl-20-oxo-19-norpregnan-21-yl)-; 3alpha-Hydroxy-3beta-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5beta-pregnan-20-one; 3beta-Methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-norpregnanolone; SAGE-217; Zurzuvae

Networked: 32 relevant articles (4 outcomes, 17 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kanes, Stephen J: 7 articles (01/2022 - 01/2019)
2.	Doherty, James: 5 articles (01/2022 - 01/2020)
3.	Gunduz-Bruce, Handan: 5 articles (01/2022 - 01/2019)
4.	Jonas, Jeffrey: 5 articles (01/2022 - 01/2019)
5.	Sankoh, Abdul J: 5 articles (01/2022 - 01/2019)
6.	Silber, Christopher: 5 articles (01/2022 - 01/2019)
7.	Bullock, Amy: 3 articles (01/2022 - 01/2020)
8.	Lasser, Robert: 3 articles (01/2022 - 01/2019)
9.	Li, Haihong: 3 articles (01/2022 - 01/2019)
10.	Werneburg, Brian: 3 articles (01/2022 - 01/2021)

Related Diseases

1.	Major Depressive Disorder (Major Depressive Disorders) 12/01/2023 - "Our study aimed to investigate the efficacy and safety of zuranolone in treating major depressive disorder (MDD). " 01/01/2023 - "Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial." 01/01/2023 - "Zuranolone in Major Depressive Disorder: Results From MOUNTAIN-A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial." 01/01/2022 - "Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder." 11/28/2019 - "Trial of SAGE-217 in Patients with Major Depressive Disorder. "
2.	Postpartum Depression (Post-Natal Depression) 12/01/2023 - "This Medical News article discusses zuranolone, the first pill approved for postpartum depression." 11/01/2023 - "In August 2023, zuranolone received its first approval in the USA for the treatment of adults with postpartum depression [pending scheduling by the US Drug Enforcement Administration (DEA)]. " 10/24/2023 - "Zuranolone: The First FDA-Approved Oral Treatment Option for Postpartum Depression." 01/01/2023 - "Zuranolone for the Treatment of Postpartum Depression." 01/01/2021 - "Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial."
3.	Sleep Initiation and Maintenance Disorders (Insomnia) 01/01/2022 - "Zuranolone improved sleep measures versus placebo in a phase advance model of insomnia in healthy adults, supporting future studies in patients with insomnia disorder." 01/01/2022 - "A phase 1 double-blind, placebo-controlled study of zuranolone (SAGE-217) in a phase advance model of insomnia in healthy adults." 01/01/2022 - "To evaluate single zuranolone (SAGE-217) 30 or 45 mg doses in a 5-h phase advance insomnia model. " 01/01/2023 - "Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression." 01/01/2023 - "The effects of zuranolone on concurrent anxiety and/or insomnia symptoms and on patient-perceived functional health in women with PPD in the ROBIN study are reported. "
4.	Tremor (Tremors) 02/15/2021 - "Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label study." 02/15/2021 - "Zuranolone was generally well tolerated and improved tremor symptoms in patients with PD who were on stable doses of concurrent dopaminergic agents. "
5.	Dizziness (Lightheadedness) 11/26/2023 - "Adverse events (AEs) such as somnolence, dizziness, and sedation were linked to zuranolone, with a higher but not statistically significant rate of discontinuation due to AEs in the zuranolone group. " 09/01/2023 - "Somnolence (placebo [3.7%], zuranolone 20 mg [10.6%], and zuranolone 30 mg [20.7%]) and dizziness (3.7%, 9.4%, and 9.8%, respectively) were more common with zuranolone. " 01/01/2023 - "The most common adverse events (≥10%) with zuranolone were somnolence, dizziness, and sedation. " 10/24/2023 - "Zuranolone was well tolerated, with somnolence, dizziness, headache, and sedation reported as the most common side effects. " 06/01/2023 - "A phase II trial conducted to evaluate the efficacy and safety of Zuranolone (30 mg, once-daily dose), described a significant reduction in total HAM-D score at day 14 and reported the drug to be well tolerated with headache, dizziness, nausea, and somnolence as the most common adverse events (AE). "

Related Drugs and Biologics

1.	Pregnanolone (Allopregnanolone)
2.	gamma-Aminobutyric Acid (GABA)
3.	Dopamine Agents (Dopaminergic Agents)
4.	Tuberculin (PPD)
5.	brexanolone
6.	Aminobutyrates (Aminobutyric Acid)
7.	Antidepressive Agents (Antidepressants)
8.	Neurosteroids
9.	zuranolone
10.	Convulsants

Related Therapies and Procedures

1.	Therapeutics